{"timestamp": "2026-01-17T23:40:44.855061", "question": "{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"Unknown\",\"given\":\"Unknown\",\"regimens\":[]},\"BIOMARKERS\":{\"AFP\":\"2.53 ng/ml (latest 2025-06-30)\",\"CA125\":\"75.00 U/ml (latest 2025-06-30)\",\"HER2\":\"Unknown\",\"MSI\":\"Unknown\",\"PDL1_CPS\":\"Unknown\",\"TMB\":\"Unknown\"},\"BRCA1\":\"Unknown\",\"BRCA2\":\"Unknown\",\"CURRENT_STATUS\":\"Consulted for surgery\",\"DIAGNOSIS\":{\"components\":[\"Peritoneal seeding\",\"Ascites\",\"Lymph node metastases\",\"Pelvic mass\"],\"histology\":\"分化差的癌\",\"laterality\":\"Bilateral\",\"primary\":\"Ovarian malignant tumor\",\"site\":\"Pelvis / adnexa\"},\"HRD\":\"Unknown\",\"INITIAL_TREATMENT\":\"Unknown\",\"LINE_OF_THERAPY\":[{\"cycles\":\"2\",\"end_date\":\"2025-06-09\",\"intent\":\"Unknown\",\"line\":\"Unknown\",\"regimen\":\"紫杉醇+卡铂\",\"start_date\":\"2025-05-09\"}],\"MAINTENANCE\":\"Unknown\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"Unknown\",\"given\":\"Unknown\",\"regimens\":[],\"start_date\":\"Unknown\"},\"NEOADJUVANT\":\"Yes\",\"PFI_days\":\"Unknown\",\"PLATINUM_HISTORY\":[{\"PFI_days\":\"Unknown\",\"end_date\":\"2025-06-09\",\"evidence\":\"\",\"evidence_type\":\"Unknown\",\"first_relapse_date\":\"Unknown\",\"line\":\"Unknown\",\"start_date\":\"2025-05-09\",\"status\":\"Unknown\"}],\"PLATINUM_PFI_CURRENT\":\"Unknown\",\"PLATINUM_STATUS\":\"Unknown\",\"PLATINUM_STATUS_CURRENT\":\"Unknown\",\"RELAPSE\":\"Unknown\",\"RELAPSE_DATE\":{\"date\":\"Unknown\",\"evidence\":\"\",\"type\":\"Unknown\"},\"STAGE\":{\"stage_basis\":\"Unknown\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"Unknown\",\"performed\":\"Unknown\",\"procedure\":\"Unknown\"},\"VISIT_DATE\":\"2025-07-01\",\"first_relapse_date\":\"Unknown\",\"last_platinum_end_date\":\"2025-06-09\"},\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"CA125\",\"history\":[{\"date\":\"2025-04-27\",\"flag\":\"Unknown\",\"value\":\"823\"},{\"date\":\"2025-06-30\",\"flag\":\"↑\",\"value\":\"75.00\"}],\"latest\":{\"date\":\"2025-06-30\",\"flag\":\"↑\",\"value\":\"75.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"HE4\",\"history\":[{\"date\":\"2025-04-27\",\"flag\":\"Unknown\",\"value\":\"480\"},{\"date\":\"2025-06-30\",\"flag\":\"↑\",\"value\":\"126.00\"}],\"latest\":{\"date\":\"2025-06-30\",\"flag\":\"↑\",\"value\":\"126.00\"},\"reference_range\":\"Unknown\",\"unit\":\"pmol/L\"},{\"analyte\":\"CA19-9\",\"history\":[{\"date\":\"2025-04-27\",\"flag\":\"Unknown\",\"value\":\"10.6\"},{\"date\":\"2025-06-30\",\"flag\":\"Unknown\",\"value\":\"17.50\"}],\"latest\":{\"date\":\"2025-06-30\",\"flag\":\"Unknown\",\"value\":\"17.50\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"CA153\",\"history\":[{\"date\":\"2025-04-27\",\"flag\":\"Unknown\",\"value\":\"294\"}],\"latest\":{\"date\":\"2025-04-27\",\"flag\":\"Unknown\",\"value\":\"294\"},\"reference_range\":\"Unknown\",\"unit\":\"Unknown\"},{\"analyte\":\"CA724\",\"history\":[{\"date\":\"2025-04-27\",\"flag\":\"Unknown\",\"value\":\"62.7\"}],\"latest\":{\"date\":\"2025-04-27\",\"flag\":\"Unknown\",\"value\":\"62.7\"},\"reference_range\":\"Unknown\",\"unit\":\"Unknown\"},{\"analyte\":\"CEA\",\"history\":[{\"date\":\"2025-04-27\",\"flag\":\"Unknown\",\"value\":\"0.8\"},{\"date\":\"2025-06-30\",\"flag\":\"Unknown\",\"value\":\"1.64\"}],\"latest\":{\"date\":\"2025-06-30\",\"flag\":\"Unknown\",\"value\":\"1.64\"},\"reference_range\":\"Unknown\",\"unit\":\"ng/ml\"},{\"analyte\":\"NSE\",\"history\":[{\"date\":\"2025-04-27\",\"flag\":\"Unknown\",\"value\":\"19.7\"}],\"latest\":{\"date\":\"2025-04-27\",\"flag\":\"Unknown\",\"value\":\"19.7\"},\"reference_range\":\"Unknown\",\"unit\":\"Unknown\"},{\"analyte\":\"AFP\",\"history\":[{\"date\":\"2025-04-27\",\"flag\":\"Unknown\",\"value\":\"2.43\"},{\"date\":\"2025-06-30\",\"flag\":\"Unknown\",\"value\":\"2.53\"}],\"latest\":{\"date\":\"2025-06-30\",\"flag\":\"Unknown\",\"value\":\"2.53\"},\"reference_range\":\"Unknown\",\"unit\":\"ng/ml\"},{\"analyte\":\"SCCA\",\"history\":[{\"date\":\"2025-04-27\",\"flag\":\"Unknown\",\"value\":\"0.92\"}],\"latest\":{\"date\":\"2025-04-27\",\"flag\":\"Unknown\",\"value\":\"0.92\"},\"reference_range\":\"Unknown\",\"unit\":\"Unknown\"},{\"analyte\":\"ROMA\",\"history\":[{\"date\":\"2025-06-30\",\"flag\":\"↑\",\"value\":\"44.54 (premenopausal)\"},{\"date\":\"2025-06-30\",\"flag\":\"↑\",\"value\":\"52.50 (postmenopausal)\"}],\"latest\":{\"date\":\"2025-06-30\",\"flag\":\"↑\",\"value\":\"52.50 (postmenopausal) / 44.54 (premenopausal)\"},\"reference_range\":\"Unknown\",\"unit\":\"%\"}],\"milestones\":[{\"date\":\"2025-04-28\",\"description\":\"Biopsy with malignant morphology\",\"type\":\"Other\"},{\"date\":\"2025-05-09\",\"description\":\"Start 紫杉醇+卡铂 (neoadjuvant)\",\"type\":\"ChemoStart\"},{\"date\":\"2025-06-09\",\"description\":\"Completed 2 cycles 紫杉醇+卡铂\",\"type\":\"ChemoEnd\"},{\"date\":\"2025-04-29\",\"description\":\"FDG-PET/CT showing widespread avid disease\",\"type\":\"Imaging\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"Completed 2 cycles of 紫杉醇+卡铂 (2025-05-09 to 2025-06-09)\",\"last_admin_date\":\"2025-06-09\",\"name\":\"Unknown\"},\"genetic_testing\":{\"germline\":[],\"somatic\":[]},\"monitoring_points\":[],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[\"紫杉醇+卡铂 (2025-05-09-2025-06-09)\"]},\"NUC_MED\":{\"studies\":[{\"avid_lesions\":[\"Bilateral adnexal lesions\",\"Left supraclavicular and bilateral internal mammary nodes\",\"Bilateral costophrenic angle nodes\",\"Abdominal, retroperitoneal, left iliac vessel nodes\",\"Multiple peritoneal and pelvic implants\"],\"confidence\":\"High\",\"date\":\"2025-04-29\",\"non_avid_notes\":[],\"type\":\"FDG-PET/CT\"}]},\"PATHOLOGY\":{\"specimens\":[{\"components\":[\"Malignant cells\",\"Poorly differentiated carcinoma (considered)\"],\"date\":\"2025-04-28\",\"diagnosis\":\"镜下形态符合恶性，考虑为分化差的癌，不排除高浆病理切片未带\",\"grade\":\"Unknown\",\"ihc\":[],\"involvement_sites\":[\"Pelvic mass\"],\"laterality\":\"Unknown\",\"molecular\":[],\"raw_text\":\"镜下形态符合恶性，考虑为分化差的癌，不排除高浆病理切片未带\",\"sample_type\":\"Core biopsy\",\"site\":\"Pelvic mass (adnexal)\",\"tumor_size\":\"Unknown\",\"uncertainty_or_missing\":[\"IHC not yet reported\"]},{\"components\":[\"Tumor cells in ascites favor adenocarcinoma\"],\"date\":\"2025-05-07\",\"diagnosis\":\"倾向腺癌\",\"grade\":\"Unknown\",\"ihc\":[],\"involvement_sites\":[\"Peritoneal cavity\"],\"laterality\":\"Unknown\",\"molecular\":[],\"raw_text\":\"腹水冲洗液见肿瘤细胞， 倾向腺癌。建议行细胞块及免疫酶标检查帮助诊断。\",\"sample_type\":\"Cytology (ascites)\",\"site\":\"Ascites\",\"tumor_size\":\"Unknown\",\"uncertainty_or_missing\":[\"Cell block and IHC recommended\"]},{\"components\":[\"Malignant tumor cells, favors adenocarcinoma\"],\"date\":\"2025-05-08\",\"diagnosis\":\"腹水细胞块切片内见恶性肿瘤细胞，倾向腺癌\",\"grade\":\"Unknown\",\"ihc\":[],\"involvement_sites\":[\"Peritoneal cavity\"],\"laterality\":\"Unknown\",\"molecular\":[],\"raw_text\":\"常规报告（2025.05.08）：腹水细胞块切片内见恶性肿瘤细胞，倾向腺癌。建议行免疫酶标检查帮助诊断。\",\"sample_type\":\"Cell block\",\"site\":\"Ascites cell block\",\"tumor_size\":\"Unknown\",\"uncertainty_or_missing\":[\"IHC recommended\"]}]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"Bilateral adnexa\",\"Peritoneum\",\"Uterus\",\"Pelvis\"],\"date\":\"2025-04-26\",\"findings\":[\"Bilateral adnexal masses (left 59x74x92 mm)\",\"Extensive peritoneal implants\",\"Moderate ascites\",\"Multiple enlarged lymph nodes (left iliac vessel, retroperitoneal, cardiophrenic)\"],\"impression\":\"Bilateral adnexal lesions suspicious for malignancy with peritoneal metastases and ascites\",\"modality\":\"CT\",\"trend_vs_prior\":\"Unknown\"},{\"anatomic_sites\":[\"Peritoneum\",\"Mesentery\",\"Liver-gastric space\",\"Retroperitoneum\"],\"date\":\"2025-07-01\",\"findings\":[\"Multiple small enhancing peritoneal and mesenteric nodules\",\"Peritoneal/mesenteric slight hazy thickening\",\"Scattered small retroperitoneal lymph nodes\",\"Liver cysts\",\"Cholelithiasis\"],\"impression\":\"Peritoneal and mesenteric enhancing nodules consistent with peritoneal disease; retroperitoneal nodes; correlate clinically\",\"modality\":\"CT\",\"trend_vs_prior\":\"Unknown\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2025-04-26\",\"description\":\"External CT: bilateral adnexal masses (left 59x74x92 mm), extensive peritoneal implants, moderate ascites, multiple enlarged nodes suspicious for metastasis\",\"event_type\":\"Imaging\",\"key_result\":\"Bilateral adnexal masses; peritoneal metastases suspected\",\"regimen_or_test\":\"CT\"},{\"date\":\"2025-04-27\",\"description\":\"Tumor markers drawn\",\"event_type\":\"Lab\",\"key_result\":\"CA125 823; CA153 294; CA724 62.7; CEA 0.8; NSE 19.7; CA199 10.6; HE4 480; AFP 2.43; SCCA 0.92\",\"regimen_or_test\":\"CA125, CA153, CA724, CEA, NSE, CA199, HE4, AFP, SCCA\"},{\"date\":\"2025-04-28\",\"description\":\"Ultrasound-guided paracentesis with drain and pelvic mass core biopsy\",\"event_type\":\"Other\",\"key_result\":\"Biopsy: morphology consistent with malignancy; considered poorly differentiated carcinoma\",\"regimen_or_test\":\"Paracentesis and biopsy\"},{\"date\":\"2025-04-29\",\"description\":\"External PET/CT showed FDG-avid bilateral adnexal lesions, multiple FDG-avid lymph nodes and peritoneal implants\",\"event_type\":\"Imaging\",\"key_result\":\"Metastatic disease suspected\",\"regimen_or_test\":\"PET/CT\"},{\"date\":\"2025-05-07\",\"description\":\"Ascites cytology: tumor cells present, favor adenocarcinoma; recommended cell block and IHC\",\"event_type\":\"Lab\",\"key_result\":\"Tumor cells present; favors adenocarcinoma\",\"regimen_or_test\":\"Ascites cytology\"},{\"date\":\"2025-05-09\",\"description\":\"Start chemotherapy: 紫杉醇+卡铂 neoadjuvant\",\"event_type\":\"Chemo\",\"key_result\":\"Planned 2 cycles (neoadjuvant)\",\"regimen_or_test\":\"紫杉醇+卡铂\"},{\"date\":\"2025-06-09\",\"description\":\"Completed 2 cycles of 紫杉醇+卡铂\",\"event_type\":\"Chemo\",\"key_result\":\"End of listed chemotherapy course\",\"regimen_or_test\":\"紫杉醇+卡铂\"},{\"date\":\"2025-06-30\",\"description\":\"Repeat tumor markers\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9 17.50 U/ml; CA125 75.00 U/ml↑; AFP 2.53 ng/ml; CEA 1.64 ng/ml; HE4 126.00 pmol/L↑; ROMA 44.54% (premenopausal)↑; ROMA 52.50% (postmenopausal)↑\",\"regimen_or_test\":\"CA19-9, CA125, AFP, CEA, HE4, ROMA\"},{\"date\":\"2025-07-01\",\"description\":\"CT: multiple small enhancing peritoneal and mesenteric nodules, scanty peritoneal thickening, scattered small retroperitoneal nodes\",\"event_type\":\"Imaging\",\"key_result\":\"Peritoneal/mesenteric nodules; follow clinical correlation\",\"regimen_or_test\":\"CT\"}]}}", "final_output": "Final Assessment:\nAdvanced epithelial adnexal malignancy with peritoneal and nodal disease on neoadjuvant platinum–taxane, but histologic subtype, response, and operability remain insufficiently characterized for definitive surgical versus systemic sequencing decisions.\n\nCore Treatment Strategy:\n- Do not commit today to interval debulking; await structured radiology response and resectability assessment integrating CT and PET findings (requested, pending).  \n- Obtain urgent comprehensive preoperative assessment (ECOG, comorbidities, nutrition, anesthetic risk, chemo tolerance) to determine surgical fitness and perioperative risk.  \n- Complete IHC and finalize histology (subtype, grade, primary site), then proceed with germline and somatic profiling to plan maintenance.  \n- Maintain platinum-taxane–based systemic strategy in principle, but adjust intensity and timing only after imaging, pathology, molecular, and fitness data are integrated.  \n\nChange Triggers:\n- If imaging shows substantial response and disease judged resectable with acceptable risk, shift toward interval debulking followed by systemic/maintenance therapy.  \n- If imaging or fitness assessment indicates unresectable disease or prohibitive surgical risk, prioritize continued systemic therapy and defer debulking, reassessing periodically.", "initial_ops": {"chair": "- Advanced ovarian malignancy with peritoneal and nodal spread; partial biochemical response to two neoadjuvant platinum–taxane cycles.  \n- Before surgery decision, urgently need updated performance status, comorbidities, nutritional status, and anesthetic risk assessment.  \n- Require standardized radiology comparison (baseline vs 2025-07-01 CT and prior PET/CT) to quantify response and resectability.  \n- Pathology incomplete: need IHC, definitive histologic subtype, grade, and tumor origin confirmation; then order germline and somatic profiling (BRCA/HRD).  \n- MDT to decide: interval debulking feasibility vs further neoadjuvant therapy once operability, pathology, and genetics are clarified.", "oncologist": "- Advanced bilateral ovarian carcinoma with peritoneal, nodal, ascitic disease; currently post‑2 cycles neoadjuvant platinum‑taxane, evaluated for interval debulking.  \n\n- Tumor markers (CA125, HE4, ROMA) substantially decreased but still elevated, suggesting partial response; detailed radiologic response assessment missing, needs updated CT/MRI.  \n\n- Organ function, performance status, neuropathy, marrow and renal reserves are unknown/needs update to judge feasibility of continued platinum‑taxane and perioperative risk.  \n\n- Germline and somatic mutation status (BRCA, HRR genes, MSI, others) unknown/needs update to plan postoperative maintenance and future systemic options.  \n\n- Surgical team’s assessment of resectability and planned timing/extent of cytoreduction is unknown/needs update to coordinate systemic therapy sequencing.", "radiologist": "- CT shows multiple small enhancing peritoneal and mesenteric nodules, consistent with disseminated peritoneal disease.[@IMAGING_STUDIES|2025-07-01]\n\n- Scattered small retroperitoneal lymph nodes; size and progression versus prior unclear, recommend comparison with earlier imaging.[@IMAGING_STUDIES|2025-07-01]\n\n- Prior CT demonstrated large bilateral adnexal masses with extensive peritoneal implants, ascites, and nodal disease, suggesting advanced pelvic malignancy.[@IMAGING_STUDIES|2025-04-26]\n\n- PET/CT previously showed widespread FDG-avid pelvic, peritoneal, and nodal disease including supradiaphragmatic nodes, confirming systemic metastatic involvement.[@PET_IF_AVAILABLE|2025-04-29]\n\n- Trend of adnexal masses, ascites volume, and nodal size between April and July CTs is unknown; need formal side-by-side comparison.", "pathologist": "- Current material supports malignant epithelial tumor, favor adenocarcinoma, from pelvic/adnexal mass with malignant ascites cytology [@HISTOLOGY_AND_IHC|2025-04-28;2025-05-07;2025-05-08].  \n- Tumor grade, exact subtype (e.g., high‑grade serous vs others), and primary site remain undetermined/uncertain [@HISTOLOGY_AND_IHC|2025-04-28].  \n- No immunohistochemistry yet on core biopsy or ascites cell block; IHC panel urgently needed for definitive classification [@HISTOLOGY_AND_IHC|2025-05-08].  \n- No molecular testing (HRD/BRCA, MSI, TMB, HER2, PD‑L1) reported; comprehensive predictive panel status unknown/needs update.  \n- Staging information (imaging, surgical findings, peritoneal/organ involvement extent) missing; pathologic stage cannot be assigned, needs radiology/surgical reports.", "nuclear": "- FDG-avid bilateral adnexal lesions with extensive peritoneal and pelvic implants indicate metabolically active adnexal primary with peritoneal carcinomatosis [@PET_CT|2025-04-29].  \n- FDG-avid retroperitoneal, left iliac, costophrenic, internal mammary, and left supraclavicular nodes suggest disseminated nodal metastases, upstaging beyond locoregional disease [@PET_CT|2025-04-29].  \n- PET/CT extends CT findings by confirming metabolic activity of peritoneal and nodal disease, strengthening suspicion for advanced-stage ovarian malignancy [@PET_CT|2025-04-29; @IMAGING_CONTEXT|2025-04-26].  \n- PET meaningfully changes staging by demonstrating extra-abdominal nodal involvement (internal mammary, supraclavicular), implying at least distant metastatic spread [@PET_CT|2025-04-29].  \n- For current visit, need histology, CA-125, prior treatments, and interval imaging to assess for recurrence vs. untreated advanced presentation (unknown/needs update)."}, "merged_summary": "Key Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supraclavicular nodes.\n- Partial biochemical response after 2 cycles of neoadjuvant platinum–taxane (markers down but still elevated).\n- PET/CT confirms metabolically active peritoneal and nodal disease intra‑ and extra‑abdominally.\n- Pathology confirms malignant epithelial (likely adnexal adenocarcinoma), but subtype, grade, and primary site remain undefined.\n\nControversies:\n- Interval debulking now versus further/modified neoadjuvant chemotherapy.\n- Extent/goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Future systemic and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional state, and anesthetic risk.\n- Formal, structured side‑by‑side comparison of baseline vs 01‑07‑2025 CT with PET correlation, including quantified response and detailed assessment of peritoneal and nodal resectability.\n- Final histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Request a standardized CT/PET response and resectability report (baseline vs 01‑07‑2025), focusing on peritoneal and nodal operability.\n- Complete IHC and finalize histologic classification, then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to decide timing of interval debulking versus further neoadjuvant therapy and to define postoperative/maintenance systemic strategy.", "final_round_ops": {"Round 1": {"chair": "- Defer interval debulking decision until standardized CT/PET response and resectability assessment is completed; request urgent integrated report (baseline vs 2025‑07‑01).  \n- Obtain full preoperative evaluation (performance, comorbidities, nutrition, organ function, neuropathy, anesthetic risk); surgery contingent on acceptable overall risk.  \n- Prioritize pathology work‑up: IHC, grade, and primary site assignment on core and cell‑block material; escalate if delayed.  \n- Initiate comprehensive germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, PD‑L1, HER2, others) once histologic subtype finalized.  \n- Reconvene MDT promptly with imaging, pathology, and risk data to choose between interval debulking versus additional/modified neoadjuvant and outline postoperative/maintenance strategy.", "oncologist": "- Defer decision on interval debulking versus further neoadjuvant therapy until standardized CT/PET response and resectability report is available (requested, pending).  \n\n- Urgently complete IHC on existing tissue to define subtype, grade, and primary site; initiate comprehensive germline and somatic profiling afterward.  \n\n- Arrange full preoperative assessment: performance status, comorbidities, nutritional/anesthetic risk, and detailed documentation of chemotherapy tolerance and neuropathy (currently unknown).  \n\n- Obtain up-to-date labs for marrow, renal, and hepatic function to confirm suitability for continued platinum-based therapy and potential surgery (unknown).  \n\n- Reconvene MDT once imaging, pathology, molecular, and clinical fitness data are available to finalize timing of surgery and systemic/maintenance strategy.", "radiologist": "- Arrange formal side‑by‑side review of baseline vs 2025-07-01 CT, with PET correlation, to quantify disease burden and resectability.[@IMAGING_STUDIES|2025-04-26][@IMAGING_STUDIES|2025-07-01][@PET_IF_AVAILABLE|2025-04-29]\n\n- In the comparative report, separately characterize peritoneal/mesenteric implants (size, distribution, bowel/mesenteric involvement) relevant to optimal cytoreduction.[@IMAGING_STUDIES|2025-07-01]\n\n- Systematically assess nodal disease (pelvic, para‑aortic, cardiophrenic, supraclavicular) for size, conglomeration, and relationship to major vessels/structures.[@IMAGING_STUDIES|2025-04-26][@PET_IF_AVAILABLE|2025-04-29]\n\n- Comment explicitly on imaging features predicting unresectable disease (e.g., root-of-mesentery, porta hepatis, diffuse small‑bowel serosal involvement) if present/absent.[@IMAGING_STUDIES|2025-07-01]\n\n- Deliver structured radiology response/resectability report before MDT reconvening to inform timing and extent of interval debulking.[@IMAGING_STUDIES|2025-07-01]", "pathologist": "- Maintain working diagnosis: advanced malignant epithelial adnexal tumor with peritoneal carcinomatosis and nodal metastases; precise subtype/grade unknown [@HISTOLOGY_AND_IHC|2025-04-28;2025-05-07;2025-05-08].  \n- Expedite IHC on pelvic mass biopsy and ascites cell block to define subtype, grade, and likely primary site [@HISTOLOGY_AND_IHC|2025-05-08].  \n- Once histotype/grade established, initiate comprehensive germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1); currently unknown.  \n- Request finalized, structured CT±PET baseline-versus-2025-07-01 response and resectability report to align surgical planning with pathology; pending/unknown.  \n- Reconvene MDT after IHC, molecular profiling, and imaging response report are available to integrate definitive pathology into staging and future management discussions.", "nuclear": "- Maintain current plan to delay surgical decisions until formal CT/PET side‑by‑side response and resectability report is completed (requested, pending).  \n- Prioritize urgent IHC and full histologic characterization to define subtype, grade, and primary site (currently unknown, needs update).  \n- Complete germline and somatic profiling after histology finalization to inform future systemic and maintenance strategy (currently unknown, needs update).  \n- Obtain comprehensive preoperative, anesthetic, and organ‑function assessments to clarify surgical fitness and perioperative risk (currently unknown, needs update).  \n- Reconvene MDT once imaging response/resectability, finalized pathology, and clinical fitness data are available to reassess interval debulking timing and goals."}, "Round 2": {"chair": "- Defer interval debulking decision until updated performance status, comorbidities, organ function, and chemo tolerance are documented (all currently unknown).  \n- Obtain standardized baseline vs 2025-07-01 CT comparison with PET correlation, explicitly grading peritoneal and nodal resectability (currently unknown).  \n- Expedite IHC on pelvic mass and ascites cell block to define epithelial subtype, grade, and likely primary site (unknown).  \n- Initiate germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1) once histology finalized; results will guide maintenance.  \n- Reconvene MDT promptly after imaging, pathology, and molecular updates to choose between interval debulking versus further neoadjuvant and to sequence subsequent systemic/maintenance therapy.", "oncologist": "- Defer decision on interval debulking versus further neoadjuvant therapy until structured CT/PET response and resectability report is available (currently unknown).  \n\n- Urgently obtain full preoperative assessment: ECOG status, comorbidities, nutrition, anesthetic risk, and detailed chemo tolerance/neuropathy documentation (unknown).  \n\n- Complete IHC and finalize histology (subtype, grade, primary site), then proceed with comprehensive germline and somatic profiling (all unknown).  \n\n- Update labs for marrow, renal, and hepatic function to confirm suitability for ongoing platinum-based therapy and major surgery (values unknown).  \n\n- Reconvene MDT once imaging, pathology, molecular, and clinical fitness data are available to finalize surgical timing and systemic/maintenance strategy.", "radiologist": "- Generate standardized side‑by‑side report comparing baseline 2025-04-26 CT and 2025-07-01 CT, quantifying measurable disease and response.[@IMAGING_STUDIES|2025-04-26][@IMAGING_STUDIES|2025-07-01]\n\n- Integrate 2025-04-29 PET/CT to map FDG‑avid peritoneal and nodal disease onto latest CT for operability assessment.[@PET_IF_AVAILABLE|2025-04-29][@IMAGING_STUDIES|2025-07-01]\n\n- Detail peritoneal carcinomatosis distribution, bowel/mesenteric involvement, and any imaging signs of likely unresectable disease on latest CT.[@IMAGING_STUDIES|2025-07-01]\n\n- Characterize nodal disease burden (pelvic, para‑aortic, cardiophrenic, supraclavicular) with size, conglomeration, and relation to major vessels.[@IMAGING_STUDIES|2025-04-26][@PET_IF_AVAILABLE|2025-04-29]\n\n- Deliver structured response/resectability report before MDT reconvening to guide interval debulking decisions versus further neoadjuvant therapy.[@IMAGING_STUDIES|2025-07-01]", "pathologist": "- Maintain working diagnosis: advanced malignant epithelial adnexal tumor with peritoneal carcinomatosis and nodal metastases; precise subtype/grade still unknown [@HISTOLOGY_AND_IHC|2025-04-28;2025-05-07;2025-05-08].  \n- Urgently perform IHC on pelvic core biopsy and ascites cell block to define histologic subtype, grade, and likely primary [@HISTOLOGY_AND_IHC|2025-05-08].  \n- After histotype/grade clarification, initiate comprehensive germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1); all currently unknown.  \n- Ensure radiology delivers structured baseline-versus-2025-07-01 CT with PET correlation, including quantified response and detailed resectability assessment; currently missing/unknown.  \n- Reconvene MDT when IHC, molecular profile, and standardized imaging response/resectability report are available to integrate definitive pathology into staging decisions.", "nuclear": "- Maintain plan for urgent comprehensive preoperative and anesthetic assessment; performance status and operative risk remain unknown/needs update.  \n- Proceed with a structured baseline-versus-01‑07‑2025 CT report with PET correlation to quantify response and resectability (requested, unknown/needs update).  \n- Finalize histology with IHC to define subtype, grade, and primary site before definitive staging (currently unknown/needs update).  \n- After histology, complete germline and somatic profiling to inform future systemic and maintenance strategies (currently unknown/needs update).  \n- Reconvene MDT once imaging response/resectability, finalized pathology, and clinical fitness data are available to reassess interval debulking versus further neoadjuvant therapy."}}, "interaction_log": {"Round 1": {"Turn 1": {"chair": {"chair": null, "oncologist": "Before deciding on interval debulking after only two neoadjuvant cycles, we need documented ECOG, comorbidities, organ function, and chemo tolerance, plus a clear statement of surgical fitness from anesthesia.", "radiologist": "Please provide a formal side‑by‑side response assessment comparing baseline CT/PET with 2025‑07‑01 CT, explicitly commenting on peritoneal disease burden, nodal status (including supraclavicular), and likelihood of achieving no gross residual disease.", "pathologist": "We urgently need IHC and a finalized report specifying histologic subtype, grade, and likely primary site from existing biopsy/ascites material to guide systemic and maintenance planning.", "nuclear": "If available, please comment on whether prior PET/CT suggests any sites that would predict unresectable residual disease despite aggressive cytoreduction, to inform timing and extent of surgery."}, "oncologist": {"chair": null, "oncologist": null, "radiologist": "Please provide a formal comparative report of baseline vs latest CT/PET, explicitly grading response and commenting on likelihood of complete/optimal cytoreduction, including extra-abdominal nodes.", "pathologist": "We need finalized histologic subtype, grade, and confirmed primary site with IHC as soon as possible to guide systemic and maintenance planning.", "nuclear": null}, "radiologist": {"chair": "A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision.", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": "Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions.", "radiologist": "Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology.", "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": "We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?", "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": "From imaging alone, we still have no formal baseline-versus-2025-07-01 response/resectability report integrating CT and PET; this remains critical before interval debulking decisions.", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": "Agree a standardized side‑by‑side CT/PET response and resectability assessment is missing; once requested, I can structure it around peritoneal and nodal operability."}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}, "Round 2": {"Turn 1": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}}, "agent_logs": {"chair": [{"role": "chair", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Advanced ovarian malignancy with peritoneal and nodal spread; partial biochemical response to two neoadjuvant platinum–taxane cycles.  \n- Before surgery decision, urgently need updated performance status, comorbidities, nutritional status, and anesthetic risk assessment.  \n- Require standardized radiology comparison (baseline vs 2025-07-01 CT and prior PET/CT) to quantify response and resectability.  \n- Pathology incomplete: need IHC, definitive histologic subtype, grade, and tumor origin confirmation; then order germline and somatic profiling (BRCA/HRD).  \n- MDT to decide: interval debulking feasibility vs further neoadjuvant therapy once operability, pathology, and genetics are clarified.", "timestamp": "2026-01-17T23:37:55.521121"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before deciding on interval debulking after only two neoadjuvant cycles, we need documented ECOG, comorbidities, organ function, and chemo tolerance, plus a clear statement of surgical fitness from anesthesia.\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"Please provide a formal side‑by‑side response assessment comparing baseline CT/PET with 2025‑07‑01 CT, explicitly commenting on peritoneal disease burden, nodal status (including supraclavicular), and likelihood of achieving no gross residual disease.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"We urgently need IHC and a finalized report specifying histologic subtype, grade, and likely primary site from existing biopsy/ascites material to guide systemic and maintenance planning.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"If available, please comment on whether prior PET/CT suggests any sites that would predict unresectable residual disease despite aggressive cytoreduction, to inform timing and extent of surgery.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T23:38:21.485028"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n[R1T1 DELTA] (missing): A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision. | pathologist->oncologist(missing): Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions. | pathologist->radiologist(missing): Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology. | nuclear->radiologist(missing): We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:38:33.128628"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n[R1T1 DELTA] (missing): A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision. | pathologist->oncologist(missing): Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions. | pathologist->radiologist(missing): Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology. | nuclear->radiologist(missing): We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?\n[R1T2 DELTA] radiologist->chair(unspecified): From imaging alone, we still have no formal baseline-versus-2025-07-01 response/resectability report integrating CT and PET; this remains critical before interval debulking decisions. | radiologist->nuclear(unspecified): Agree a standardized side‑by‑side CT/PET response and resectability assessment is missing; once requested, I can structure it around peritoneal and nodal operability.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Defer interval debulking decision until standardized CT/PET response and resectability assessment is completed; request urgent integrated report (baseline vs 2025‑07‑01).  \n- Obtain full preoperative evaluation (performance, comorbidities, nutrition, organ function, neuropathy, anesthetic risk); surgery contingent on acceptable overall risk.  \n- Prioritize pathology work‑up: IHC, grade, and primary site assignment on core and cell‑block material; escalate if delayed.  \n- Initiate comprehensive germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, PD‑L1, HER2, others) once histologic subtype finalized.  \n- Reconvene MDT promptly with imaging, pathology, and risk data to choose between interval debulking versus additional/modified neoadjuvant and outline postoperative/maintenance strategy.", "timestamp": "2026-01-17T23:39:02.213523"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supraclavicular nodes.\n- Partial biochemical response after 2 cycles of neoadjuvant platinum–taxane (markers down but still elevated).\n- PET/CT confirms metabolically active peritoneal and nodal disease intra‑ and extra‑abdominally.\n- Pathology confirms malignant epithelial (likely adnexal adenocarcinoma), but subtype, grade, and primary site remain undefined.\n\nControversies:\n- Interval debulking now versus further/modified neoadjuvant chemotherapy.\n- Extent/goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Future systemic and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional state, and anesthetic risk.\n- Formal, structured side‑by‑side comparison of baseline vs 01‑07‑2025 CT with PET correlation, including quantified response and detailed assessment of peritoneal and nodal resectability.\n- Final histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Request a standardized CT/PET response and resectability report (baseline vs 01‑07‑2025), focusing on peritoneal and nodal operability.\n- Complete IHC and finalize histologic classification, then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to decide timing of interval debulking versus further neoadjuvant therapy and to define postoperative/maintenance systemic strategy.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:39:38.542651"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supraclavicular nodes.\n- Partial biochemical response after 2 cycles of neoadjuvant platinum–taxane (markers down but still elevated).\n- PET/CT confirms metabolically active peritoneal and nodal disease intra‑ and extra‑abdominally.\n- Pathology confirms malignant epithelial (likely adnexal adenocarcinoma), but subtype, grade, and primary site remain undefined.\n\nControversies:\n- Interval debulking now versus further/modified neoadjuvant chemotherapy.\n- Extent/goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Future systemic and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional state, and anesthetic risk.\n- Formal, structured side‑by‑side comparison of baseline vs 01‑07‑2025 CT with PET correlation, including quantified response and detailed assessment of peritoneal and nodal resectability.\n- Final histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Request a standardized CT/PET response and resectability report (baseline vs 01‑07‑2025), focusing on peritoneal and nodal operability.\n- Complete IHC and finalize histologic classification, then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to decide timing of interval debulking versus further neoadjuvant therapy and to define postoperative/maintenance systemic strategy.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Defer interval debulking decision until updated performance status, comorbidities, organ function, and chemo tolerance are documented (all currently unknown).  \n- Obtain standardized baseline vs 2025-07-01 CT comparison with PET correlation, explicitly grading peritoneal and nodal resectability (currently unknown).  \n- Expedite IHC on pelvic mass and ascites cell block to define epithelial subtype, grade, and likely primary site (unknown).  \n- Initiate germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1) once histology finalized; results will guide maintenance.  \n- Reconvene MDT promptly after imaging, pathology, and molecular updates to choose between interval debulking versus further neoadjuvant and to sequence subsequent systemic/maintenance therapy.", "timestamp": "2026-01-17T23:40:07.632900"}, {"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2025-07-01 15:38:50.183000.\nBased on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.\n\nSTRICT RULES:\n- Any factual statement about past tests/treatments must include [@report_id|date] or say unknown.\n- If experts disagree, pick the safest plan and state the key uncertainty.\n\n# FINAL REFINED PLANS (All experts, last round)\n{\n  \"Round 1\": {\n    \"chair\": \"- Defer interval debulking decision until standardized CT/PET response and resectability assessment is completed; request urgent integrated report (baseline vs 2025‑07‑01).  \\n- Obtain full preoperative evaluation (performance, comorbidities, nutrition, organ function, neuropathy, anesthetic risk); surgery contingent on acceptable overall risk.  \\n- Prioritize pathology work‑up: IHC, grade, and primary site assignment on core and cell‑block material; escalate if delayed.  \\n- Initiate comprehensive germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, PD‑L1, HER2, others) once histologic subtype finalized.  \\n- Reconvene MDT promptly with imaging, pathology, and risk data to choose between interval debulking versus additional/modified neoadjuvant and outline postoperative/maintenance strategy.\",\n    \"oncologist\": \"- Defer decision on interval debulking versus further neoadjuvant therapy until standardized CT/PET response and resectability report is available (requested, pending).  \\n\\n- Urgently complete IHC on existing tissue to define subtype, grade, and primary site; initiate comprehensive germline and somatic profiling afterward.  \\n\\n- Arrange full preoperative assessment: performance status, comorbidities, nutritional/anesthetic risk, and detailed documentation of chemotherapy tolerance and neuropathy (currently unknown).  \\n\\n- Obtain up-to-date labs for marrow, renal, and hepatic function to confirm suitability for continued platinum-based therapy and potential surgery (unknown).  \\n\\n- Reconvene MDT once imaging, pathology, molecular, and clinical fitness data are available to finalize timing of surgery and systemic/maintenance strategy.\",\n    \"radiologist\": \"- Arrange formal side‑by‑side review of baseline vs 2025-07-01 CT, with PET correlation, to quantify disease burden and resectability.[@IMAGING_STUDIES|2025-04-26][@IMAGING_STUDIES|2025-07-01][@PET_IF_AVAILABLE|2025-04-29]\\n\\n- In the comparative report, separately characterize peritoneal/mesenteric implants (size, distribution, bowel/mesenteric involvement) relevant to optimal cytoreduction.[@IMAGING_STUDIES|2025-07-01]\\n\\n- Systematically assess nodal disease (pelvic, para‑aortic, cardiophrenic, supraclavicular) for size, conglomeration, and relationship to major vessels/structures.[@IMAGING_STUDIES|2025-04-26][@PET_IF_AVAILABLE|2025-04-29]\\n\\n- Comment explicitly on imaging features predicting unresectable disease (e.g., root-of-mesentery, porta hepatis, diffuse small‑bowel serosal involvement) if present/absent.[@IMAGING_STUDIES|2025-07-01]\\n\\n- Deliver structured radiology response/resectability report before MDT reconvening to inform timing and extent of interval debulking.[@IMAGING_STUDIES|2025-07-01]\",\n    \"pathologist\": \"- Maintain working diagnosis: advanced malignant epithelial adnexal tumor with peritoneal carcinomatosis and nodal metastases; precise subtype/grade unknown [@HISTOLOGY_AND_IHC|2025-04-28;2025-05-07;2025-05-08].  \\n- Expedite IHC on pelvic mass biopsy and ascites cell block to define subtype, grade, and likely primary site [@HISTOLOGY_AND_IHC|2025-05-08].  \\n- Once histotype/grade established, initiate comprehensive germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1); currently unknown.  \\n- Request finalized, structured CT±PET baseline-versus-2025-07-01 response and resectability report to align surgical planning with pathology; pending/unknown.  \\n- Reconvene MDT after IHC, molecular profiling, and imaging response report are available to integrate definitive pathology into staging and future management discussions.\",\n    \"nuclear\": \"- Maintain current plan to delay surgical decisions until formal CT/PET side‑by‑side response and resectability report is completed (requested, pending).  \\n- Prioritize urgent IHC and full histologic characterization to define subtype, grade, and primary site (currently unknown, needs update).  \\n- Complete germline and somatic profiling after histology finalization to inform future systemic and maintenance strategy (currently unknown, needs update).  \\n- Obtain comprehensive preoperative, anesthetic, and organ‑function assessments to clarify surgical fitness and perioperative risk (currently unknown, needs update).  \\n- Reconvene MDT once imaging response/resectability, finalized pathology, and clinical fitness data are available to reassess interval debulking timing and goals.\"\n  },\n  \"Round 2\": {\n    \"chair\": \"- Defer interval debulking decision until updated performance status, comorbidities, organ function, and chemo tolerance are documented (all currently unknown).  \\n- Obtain standardized baseline vs 2025-07-01 CT comparison with PET correlation, explicitly grading peritoneal and nodal resectability (currently unknown).  \\n- Expedite IHC on pelvic mass and ascites cell block to define epithelial subtype, grade, and likely primary site (unknown).  \\n- Initiate germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1) once histology finalized; results will guide maintenance.  \\n- Reconvene MDT promptly after imaging, pathology, and molecular updates to choose between interval debulking versus further neoadjuvant and to sequence subsequent systemic/maintenance therapy.\",\n    \"oncologist\": \"- Defer decision on interval debulking versus further neoadjuvant therapy until structured CT/PET response and resectability report is available (currently unknown).  \\n\\n- Urgently obtain full preoperative assessment: ECOG status, comorbidities, nutrition, anesthetic risk, and detailed chemo tolerance/neuropathy documentation (unknown).  \\n\\n- Complete IHC and finalize histology (subtype, grade, primary site), then proceed with comprehensive germline and somatic profiling (all unknown).  \\n\\n- Update labs for marrow, renal, and hepatic function to confirm suitability for ongoing platinum-based therapy and major surgery (values unknown).  \\n\\n- Reconvene MDT once imaging, pathology, molecular, and clinical fitness data are available to finalize surgical timing and systemic/maintenance strategy.\",\n    \"radiologist\": \"- Generate standardized side‑by‑side report comparing baseline 2025-04-26 CT and 2025-07-01 CT, quantifying measurable disease and response.[@IMAGING_STUDIES|2025-04-26][@IMAGING_STUDIES|2025-07-01]\\n\\n- Integrate 2025-04-29 PET/CT to map FDG‑avid peritoneal and nodal disease onto latest CT for operability assessment.[@PET_IF_AVAILABLE|2025-04-29][@IMAGING_STUDIES|2025-07-01]\\n\\n- Detail peritoneal carcinomatosis distribution, bowel/mesenteric involvement, and any imaging signs of likely unresectable disease on latest CT.[@IMAGING_STUDIES|2025-07-01]\\n\\n- Characterize nodal disease burden (pelvic, para‑aortic, cardiophrenic, supraclavicular) with size, conglomeration, and relation to major vessels.[@IMAGING_STUDIES|2025-04-26][@PET_IF_AVAILABLE|2025-04-29]\\n\\n- Deliver structured response/resectability report before MDT reconvening to guide interval debulking decisions versus further neoadjuvant therapy.[@IMAGING_STUDIES|2025-07-01]\",\n    \"pathologist\": \"- Maintain working diagnosis: advanced malignant epithelial adnexal tumor with peritoneal carcinomatosis and nodal metastases; precise subtype/grade still unknown [@HISTOLOGY_AND_IHC|2025-04-28;2025-05-07;2025-05-08].  \\n- Urgently perform IHC on pelvic core biopsy and ascites cell block to define histologic subtype, grade, and likely primary [@HISTOLOGY_AND_IHC|2025-05-08].  \\n- After histotype/grade clarification, initiate comprehensive germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1); all currently unknown.  \\n- Ensure radiology delivers structured baseline-versus-2025-07-01 CT with PET correlation, including quantified response and detailed resectability assessment; currently missing/unknown.  \\n- Reconvene MDT when IHC, molecular profile, and standardized imaging response/resectability report are available to integrate definitive pathology into staging decisions.\",\n    \"nuclear\": \"- Maintain plan for urgent comprehensive preoperative and anesthetic assessment; performance status and operative risk remain unknown/needs update.  \\n- Proceed with a structured baseline-versus-01‑07‑2025 CT report with PET correlation to quantify response and resectability (requested, unknown/needs update).  \\n- Finalize histology with IHC to define subtype, grade, and primary site before definitive staging (currently unknown/needs update).  \\n- After histology, complete germline and somatic profiling to inform future systemic and maintenance strategies (currently unknown/needs update).  \\n- Reconvene MDT once imaging response/resectability, finalized pathology, and clinical fitness data are available to reassess interval debulking versus further neoadjuvant therapy.\"\n  }\n}\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n\nChange Triggers:\n- < ≤20 words “if X, then adjust management from A to B” >\n- < ≤20 words “if X, then adjust management from A to B” >\n", "assistant_reply": "Final Assessment:\nAdvanced epithelial adnexal malignancy with peritoneal and nodal disease on neoadjuvant platinum–taxane, but histologic subtype, response, and operability remain insufficiently characterized for definitive surgical versus systemic sequencing decisions.\n\nCore Treatment Strategy:\n- Do not commit today to interval debulking; await structured radiology response and resectability assessment integrating CT and PET findings (requested, pending).  \n- Obtain urgent comprehensive preoperative assessment (ECOG, comorbidities, nutrition, anesthetic risk, chemo tolerance) to determine surgical fitness and perioperative risk.  \n- Complete IHC and finalize histology (subtype, grade, primary site), then proceed with germline and somatic profiling to plan maintenance.  \n- Maintain platinum-taxane–based systemic strategy in principle, but adjust intensity and timing only after imaging, pathology, molecular, and fitness data are integrated.  \n\nChange Triggers:\n- If imaging shows substantial response and disease judged resectable with acceptable risk, shift toward interval debulking followed by systemic/maintenance therapy.  \n- If imaging or fitness assessment indicates unresectable disease or prohibitive surgical risk, prioritize continued systemic therapy and defer debulking, reassessing periodically.", "timestamp": "2026-01-17T23:40:44.854842"}], "oncologist": [{"role": "oncologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Advanced bilateral ovarian carcinoma with peritoneal, nodal, ascitic disease; currently post‑2 cycles neoadjuvant platinum‑taxane, evaluated for interval debulking.  \n\n- Tumor markers (CA125, HE4, ROMA) substantially decreased but still elevated, suggesting partial response; detailed radiologic response assessment missing, needs updated CT/MRI.  \n\n- Organ function, performance status, neuropathy, marrow and renal reserves are unknown/needs update to judge feasibility of continued platinum‑taxane and perioperative risk.  \n\n- Germline and somatic mutation status (BRCA, HRR genes, MSI, others) unknown/needs update to plan postoperative maintenance and future systemic options.  \n\n- Surgical team’s assessment of resectability and planned timing/extent of cytoreduction is unknown/needs update to coordinate systemic therapy sequencing.", "timestamp": "2026-01-17T23:37:58.180203"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"radiologist\",\"message\":\"Please provide a formal comparative report of baseline vs latest CT/PET, explicitly grading response and commenting on likelihood of complete/optimal cytoreduction, including extra-abdominal nodes.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"We need finalized histologic subtype, grade, and confirmed primary site with IHC as soon as possible to guide systemic and maintenance planning.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T23:38:24.869701"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n[R1T1 DELTA] (missing): A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision. | pathologist->oncologist(missing): Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions. | pathologist->radiologist(missing): Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology. | nuclear->radiologist(missing): We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:38:34.828881"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n[R1T1 DELTA] (missing): A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision. | pathologist->oncologist(missing): Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions. | pathologist->radiologist(missing): Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology. | nuclear->radiologist(missing): We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?\n[R1T2 DELTA] radiologist->chair(unspecified): From imaging alone, we still have no formal baseline-versus-2025-07-01 response/resectability report integrating CT and PET; this remains critical before interval debulking decisions. | radiologist->nuclear(unspecified): Agree a standardized side‑by‑side CT/PET response and resectability assessment is missing; once requested, I can structure it around peritoneal and nodal operability.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Defer decision on interval debulking versus further neoadjuvant therapy until standardized CT/PET response and resectability report is available (requested, pending).  \n\n- Urgently complete IHC on existing tissue to define subtype, grade, and primary site; initiate comprehensive germline and somatic profiling afterward.  \n\n- Arrange full preoperative assessment: performance status, comorbidities, nutritional/anesthetic risk, and detailed documentation of chemotherapy tolerance and neuropathy (currently unknown).  \n\n- Obtain up-to-date labs for marrow, renal, and hepatic function to confirm suitability for continued platinum-based therapy and potential surgery (unknown).  \n\n- Reconvene MDT once imaging, pathology, molecular, and clinical fitness data are available to finalize timing of surgery and systemic/maintenance strategy.", "timestamp": "2026-01-17T23:39:06.279001"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supraclavicular nodes.\n- Partial biochemical response after 2 cycles of neoadjuvant platinum–taxane (markers down but still elevated).\n- PET/CT confirms metabolically active peritoneal and nodal disease intra‑ and extra‑abdominally.\n- Pathology confirms malignant epithelial (likely adnexal adenocarcinoma), but subtype, grade, and primary site remain undefined.\n\nControversies:\n- Interval debulking now versus further/modified neoadjuvant chemotherapy.\n- Extent/goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Future systemic and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional state, and anesthetic risk.\n- Formal, structured side‑by‑side comparison of baseline vs 01‑07‑2025 CT with PET correlation, including quantified response and detailed assessment of peritoneal and nodal resectability.\n- Final histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Request a standardized CT/PET response and resectability report (baseline vs 01‑07‑2025), focusing on peritoneal and nodal operability.\n- Complete IHC and finalize histologic classification, then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to decide timing of interval debulking versus further neoadjuvant therapy and to define postoperative/maintenance systemic strategy.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:39:40.071690"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supraclavicular nodes.\n- Partial biochemical response after 2 cycles of neoadjuvant platinum–taxane (markers down but still elevated).\n- PET/CT confirms metabolically active peritoneal and nodal disease intra‑ and extra‑abdominally.\n- Pathology confirms malignant epithelial (likely adnexal adenocarcinoma), but subtype, grade, and primary site remain undefined.\n\nControversies:\n- Interval debulking now versus further/modified neoadjuvant chemotherapy.\n- Extent/goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Future systemic and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional state, and anesthetic risk.\n- Formal, structured side‑by‑side comparison of baseline vs 01‑07‑2025 CT with PET correlation, including quantified response and detailed assessment of peritoneal and nodal resectability.\n- Final histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Request a standardized CT/PET response and resectability report (baseline vs 01‑07‑2025), focusing on peritoneal and nodal operability.\n- Complete IHC and finalize histologic classification, then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to decide timing of interval debulking versus further neoadjuvant therapy and to define postoperative/maintenance systemic strategy.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Defer decision on interval debulking versus further neoadjuvant therapy until structured CT/PET response and resectability report is available (currently unknown).  \n\n- Urgently obtain full preoperative assessment: ECOG status, comorbidities, nutrition, anesthetic risk, and detailed chemo tolerance/neuropathy documentation (unknown).  \n\n- Complete IHC and finalize histology (subtype, grade, primary site), then proceed with comprehensive germline and somatic profiling (all unknown).  \n\n- Update labs for marrow, renal, and hepatic function to confirm suitability for ongoing platinum-based therapy and major surgery (values unknown).  \n\n- Reconvene MDT once imaging, pathology, molecular, and clinical fitness data are available to finalize surgical timing and systemic/maintenance strategy.", "timestamp": "2026-01-17T23:40:25.408669"}], "radiologist": [{"role": "radiologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- CT shows multiple small enhancing peritoneal and mesenteric nodules, consistent with disseminated peritoneal disease.[@IMAGING_STUDIES|2025-07-01]\n\n- Scattered small retroperitoneal lymph nodes; size and progression versus prior unclear, recommend comparison with earlier imaging.[@IMAGING_STUDIES|2025-07-01]\n\n- Prior CT demonstrated large bilateral adnexal masses with extensive peritoneal implants, ascites, and nodal disease, suggesting advanced pelvic malignancy.[@IMAGING_STUDIES|2025-04-26]\n\n- PET/CT previously showed widespread FDG-avid pelvic, peritoneal, and nodal disease including supradiaphragmatic nodes, confirming systemic metastatic involvement.[@PET_IF_AVAILABLE|2025-04-29]\n\n- Trend of adnexal masses, ascites volume, and nodal size between April and July CTs is unknown; need formal side-by-side comparison.", "timestamp": "2026-01-17T23:38:01.069562"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T23:38:26.289895"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n[R1T1 DELTA] (missing): A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision. | pathologist->oncologist(missing): Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions. | pathologist->radiologist(missing): Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology. | nuclear->radiologist(missing): We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"From imaging alone, we still have no formal baseline-versus-2025-07-01 response/resectability report integrating CT and PET; this remains critical before interval debulking decisions.\",\"why\":\"missing-critical\"},{\"target\":\"nuclear\",\"message\":\"Agree a standardized side‑by‑side CT/PET response and resectability assessment is missing; once requested, I can structure it around peritoneal and nodal operability.\",\"why\":\"missing-critical\"}]}", "timestamp": "2026-01-17T23:38:37.470873"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n[R1T1 DELTA] (missing): A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision. | pathologist->oncologist(missing): Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions. | pathologist->radiologist(missing): Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology. | nuclear->radiologist(missing): We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?\n[R1T2 DELTA] radiologist->chair(unspecified): From imaging alone, we still have no formal baseline-versus-2025-07-01 response/resectability report integrating CT and PET; this remains critical before interval debulking decisions. | radiologist->nuclear(unspecified): Agree a standardized side‑by‑side CT/PET response and resectability assessment is missing; once requested, I can structure it around peritoneal and nodal operability.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Arrange formal side‑by‑side review of baseline vs 2025-07-01 CT, with PET correlation, to quantify disease burden and resectability.[@IMAGING_STUDIES|2025-04-26][@IMAGING_STUDIES|2025-07-01][@PET_IF_AVAILABLE|2025-04-29]\n\n- In the comparative report, separately characterize peritoneal/mesenteric implants (size, distribution, bowel/mesenteric involvement) relevant to optimal cytoreduction.[@IMAGING_STUDIES|2025-07-01]\n\n- Systematically assess nodal disease (pelvic, para‑aortic, cardiophrenic, supraclavicular) for size, conglomeration, and relationship to major vessels/structures.[@IMAGING_STUDIES|2025-04-26][@PET_IF_AVAILABLE|2025-04-29]\n\n- Comment explicitly on imaging features predicting unresectable disease (e.g., root-of-mesentery, porta hepatis, diffuse small‑bowel serosal involvement) if present/absent.[@IMAGING_STUDIES|2025-07-01]\n\n- Deliver structured radiology response/resectability report before MDT reconvening to inform timing and extent of interval debulking.[@IMAGING_STUDIES|2025-07-01]", "timestamp": "2026-01-17T23:39:23.701547"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supraclavicular nodes.\n- Partial biochemical response after 2 cycles of neoadjuvant platinum–taxane (markers down but still elevated).\n- PET/CT confirms metabolically active peritoneal and nodal disease intra‑ and extra‑abdominally.\n- Pathology confirms malignant epithelial (likely adnexal adenocarcinoma), but subtype, grade, and primary site remain undefined.\n\nControversies:\n- Interval debulking now versus further/modified neoadjuvant chemotherapy.\n- Extent/goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Future systemic and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional state, and anesthetic risk.\n- Formal, structured side‑by‑side comparison of baseline vs 01‑07‑2025 CT with PET correlation, including quantified response and detailed assessment of peritoneal and nodal resectability.\n- Final histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Request a standardized CT/PET response and resectability report (baseline vs 01‑07‑2025), focusing on peritoneal and nodal operability.\n- Complete IHC and finalize histologic classification, then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to decide timing of interval debulking versus further neoadjuvant therapy and to define postoperative/maintenance systemic strategy.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:39:41.588333"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supraclavicular nodes.\n- Partial biochemical response after 2 cycles of neoadjuvant platinum–taxane (markers down but still elevated).\n- PET/CT confirms metabolically active peritoneal and nodal disease intra‑ and extra‑abdominally.\n- Pathology confirms malignant epithelial (likely adnexal adenocarcinoma), but subtype, grade, and primary site remain undefined.\n\nControversies:\n- Interval debulking now versus further/modified neoadjuvant chemotherapy.\n- Extent/goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Future systemic and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional state, and anesthetic risk.\n- Formal, structured side‑by‑side comparison of baseline vs 01‑07‑2025 CT with PET correlation, including quantified response and detailed assessment of peritoneal and nodal resectability.\n- Final histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Request a standardized CT/PET response and resectability report (baseline vs 01‑07‑2025), focusing on peritoneal and nodal operability.\n- Complete IHC and finalize histologic classification, then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to decide timing of interval debulking versus further neoadjuvant therapy and to define postoperative/maintenance systemic strategy.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Generate standardized side‑by‑side report comparing baseline 2025-04-26 CT and 2025-07-01 CT, quantifying measurable disease and response.[@IMAGING_STUDIES|2025-04-26][@IMAGING_STUDIES|2025-07-01]\n\n- Integrate 2025-04-29 PET/CT to map FDG‑avid peritoneal and nodal disease onto latest CT for operability assessment.[@PET_IF_AVAILABLE|2025-04-29][@IMAGING_STUDIES|2025-07-01]\n\n- Detail peritoneal carcinomatosis distribution, bowel/mesenteric involvement, and any imaging signs of likely unresectable disease on latest CT.[@IMAGING_STUDIES|2025-07-01]\n\n- Characterize nodal disease burden (pelvic, para‑aortic, cardiophrenic, supraclavicular) with size, conglomeration, and relation to major vessels.[@IMAGING_STUDIES|2025-04-26][@PET_IF_AVAILABLE|2025-04-29]\n\n- Deliver structured response/resectability report before MDT reconvening to guide interval debulking decisions versus further neoadjuvant therapy.[@IMAGING_STUDIES|2025-07-01]", "timestamp": "2026-01-17T23:40:28.671252"}], "pathologist": [{"role": "pathologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Current material supports malignant epithelial tumor, favor adenocarcinoma, from pelvic/adnexal mass with malignant ascites cytology [@HISTOLOGY_AND_IHC|2025-04-28;2025-05-07;2025-05-08].  \n- Tumor grade, exact subtype (e.g., high‑grade serous vs others), and primary site remain undetermined/uncertain [@HISTOLOGY_AND_IHC|2025-04-28].  \n- No immunohistochemistry yet on core biopsy or ascites cell block; IHC panel urgently needed for definitive classification [@HISTOLOGY_AND_IHC|2025-05-08].  \n- No molecular testing (HRD/BRCA, MSI, TMB, HER2, PD‑L1) reported; comprehensive predictive panel status unknown/needs update.  \n- Staging information (imaging, surgical findings, peritoneal/organ involvement extent) missing; pathologic stage cannot be assigned, needs radiology/surgical reports.", "timestamp": "2026-01-17T23:38:04.021702"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions.\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T23:38:28.552559"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n[R1T1 DELTA] (missing): A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision. | pathologist->oncologist(missing): Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions. | pathologist->radiologist(missing): Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology. | nuclear->radiologist(missing): We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:38:39.975220"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n[R1T1 DELTA] (missing): A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision. | pathologist->oncologist(missing): Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions. | pathologist->radiologist(missing): Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology. | nuclear->radiologist(missing): We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?\n[R1T2 DELTA] radiologist->chair(unspecified): From imaging alone, we still have no formal baseline-versus-2025-07-01 response/resectability report integrating CT and PET; this remains critical before interval debulking decisions. | radiologist->nuclear(unspecified): Agree a standardized side‑by‑side CT/PET response and resectability assessment is missing; once requested, I can structure it around peritoneal and nodal operability.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Maintain working diagnosis: advanced malignant epithelial adnexal tumor with peritoneal carcinomatosis and nodal metastases; precise subtype/grade unknown [@HISTOLOGY_AND_IHC|2025-04-28;2025-05-07;2025-05-08].  \n- Expedite IHC on pelvic mass biopsy and ascites cell block to define subtype, grade, and likely primary site [@HISTOLOGY_AND_IHC|2025-05-08].  \n- Once histotype/grade established, initiate comprehensive germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1); currently unknown.  \n- Request finalized, structured CT±PET baseline-versus-2025-07-01 response and resectability report to align surgical planning with pathology; pending/unknown.  \n- Reconvene MDT after IHC, molecular profiling, and imaging response report are available to integrate definitive pathology into staging and future management discussions.", "timestamp": "2026-01-17T23:39:27.314680"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supraclavicular nodes.\n- Partial biochemical response after 2 cycles of neoadjuvant platinum–taxane (markers down but still elevated).\n- PET/CT confirms metabolically active peritoneal and nodal disease intra‑ and extra‑abdominally.\n- Pathology confirms malignant epithelial (likely adnexal adenocarcinoma), but subtype, grade, and primary site remain undefined.\n\nControversies:\n- Interval debulking now versus further/modified neoadjuvant chemotherapy.\n- Extent/goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Future systemic and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional state, and anesthetic risk.\n- Formal, structured side‑by‑side comparison of baseline vs 01‑07‑2025 CT with PET correlation, including quantified response and detailed assessment of peritoneal and nodal resectability.\n- Final histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Request a standardized CT/PET response and resectability report (baseline vs 01‑07‑2025), focusing on peritoneal and nodal operability.\n- Complete IHC and finalize histologic classification, then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to decide timing of interval debulking versus further neoadjuvant therapy and to define postoperative/maintenance systemic strategy.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:39:43.124604"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supraclavicular nodes.\n- Partial biochemical response after 2 cycles of neoadjuvant platinum–taxane (markers down but still elevated).\n- PET/CT confirms metabolically active peritoneal and nodal disease intra‑ and extra‑abdominally.\n- Pathology confirms malignant epithelial (likely adnexal adenocarcinoma), but subtype, grade, and primary site remain undefined.\n\nControversies:\n- Interval debulking now versus further/modified neoadjuvant chemotherapy.\n- Extent/goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Future systemic and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional state, and anesthetic risk.\n- Formal, structured side‑by‑side comparison of baseline vs 01‑07‑2025 CT with PET correlation, including quantified response and detailed assessment of peritoneal and nodal resectability.\n- Final histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Request a standardized CT/PET response and resectability report (baseline vs 01‑07‑2025), focusing on peritoneal and nodal operability.\n- Complete IHC and finalize histologic classification, then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to decide timing of interval debulking versus further neoadjuvant therapy and to define postoperative/maintenance systemic strategy.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Maintain working diagnosis: advanced malignant epithelial adnexal tumor with peritoneal carcinomatosis and nodal metastases; precise subtype/grade still unknown [@HISTOLOGY_AND_IHC|2025-04-28;2025-05-07;2025-05-08].  \n- Urgently perform IHC on pelvic core biopsy and ascites cell block to define histologic subtype, grade, and likely primary [@HISTOLOGY_AND_IHC|2025-05-08].  \n- After histotype/grade clarification, initiate comprehensive germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1); all currently unknown.  \n- Ensure radiology delivers structured baseline-versus-2025-07-01 CT with PET correlation, including quantified response and detailed resectability assessment; currently missing/unknown.  \n- Reconvene MDT when IHC, molecular profile, and standardized imaging response/resectability report are available to integrate definitive pathology into staging decisions.", "timestamp": "2026-01-17T23:40:35.897343"}], "nuclear": [{"role": "nuclear", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- FDG-avid bilateral adnexal lesions with extensive peritoneal and pelvic implants indicate metabolically active adnexal primary with peritoneal carcinomatosis [@PET_CT|2025-04-29].  \n- FDG-avid retroperitoneal, left iliac, costophrenic, internal mammary, and left supraclavicular nodes suggest disseminated nodal metastases, upstaging beyond locoregional disease [@PET_CT|2025-04-29].  \n- PET/CT extends CT findings by confirming metabolic activity of peritoneal and nodal disease, strengthening suspicion for advanced-stage ovarian malignancy [@PET_CT|2025-04-29; @IMAGING_CONTEXT|2025-04-26].  \n- PET meaningfully changes staging by demonstrating extra-abdominal nodal involvement (internal mammary, supraclavicular), implying at least distant metastatic spread [@PET_CT|2025-04-29].  \n- For current visit, need histology, CA-125, prior treatments, and interval imaging to assess for recurrence vs. untreated advanced presentation (unknown/needs update).", "timestamp": "2026-01-17T23:38:07.366867"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"radiologist\",\"message\":\"We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T23:38:31.542451"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n[R1T1 DELTA] (missing): A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision. | pathologist->oncologist(missing): Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions. | pathologist->radiologist(missing): Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology. | nuclear->radiologist(missing): We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:38:43.211920"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n[R1T1 DELTA] (missing): A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision. | pathologist->oncologist(missing): Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions. | pathologist->radiologist(missing): Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology. | nuclear->radiologist(missing): We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?\n[R1T2 DELTA] radiologist->chair(unspecified): From imaging alone, we still have no formal baseline-versus-2025-07-01 response/resectability report integrating CT and PET; this remains critical before interval debulking decisions. | radiologist->nuclear(unspecified): Agree a standardized side‑by‑side CT/PET response and resectability assessment is missing; once requested, I can structure it around peritoneal and nodal operability.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Maintain current plan to delay surgical decisions until formal CT/PET side‑by‑side response and resectability report is completed (requested, pending).  \n- Prioritize urgent IHC and full histologic characterization to define subtype, grade, and primary site (currently unknown, needs update).  \n- Complete germline and somatic profiling after histology finalization to inform future systemic and maintenance strategy (currently unknown, needs update).  \n- Obtain comprehensive preoperative, anesthetic, and organ‑function assessments to clarify surgical fitness and perioperative risk (currently unknown, needs update).  \n- Reconvene MDT once imaging response/resectability, finalized pathology, and clinical fitness data are available to reassess interval debulking timing and goals.", "timestamp": "2026-01-17T23:39:31.138381"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-07-01 15:38:50.183000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supraclavicular nodes.\n- Partial biochemical response after 2 cycles of neoadjuvant platinum–taxane (markers down but still elevated).\n- PET/CT confirms metabolically active peritoneal and nodal disease intra‑ and extra‑abdominally.\n- Pathology confirms malignant epithelial (likely adnexal adenocarcinoma), but subtype, grade, and primary site remain undefined.\n\nControversies:\n- Interval debulking now versus further/modified neoadjuvant chemotherapy.\n- Extent/goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Future systemic and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional state, and anesthetic risk.\n- Formal, structured side‑by‑side comparison of baseline vs 01‑07‑2025 CT with PET correlation, including quantified response and detailed assessment of peritoneal and nodal resectability.\n- Final histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Request a standardized CT/PET response and resectability report (baseline vs 01‑07‑2025), focusing on peritoneal and nodal operability.\n- Complete IHC and finalize histologic classification, then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to decide timing of interval debulking versus further neoadjuvant therapy and to define postoperative/maintenance systemic strategy.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T23:40:03.783866"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supraclavicular nodes.\n- Partial biochemical response after 2 cycles of neoadjuvant platinum–taxane (markers down but still elevated).\n- PET/CT confirms metabolically active peritoneal and nodal disease intra‑ and extra‑abdominally.\n- Pathology confirms malignant epithelial (likely adnexal adenocarcinoma), but subtype, grade, and primary site remain undefined.\n\nControversies:\n- Interval debulking now versus further/modified neoadjuvant chemotherapy.\n- Extent/goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Future systemic and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional state, and anesthetic risk.\n- Formal, structured side‑by‑side comparison of baseline vs 01‑07‑2025 CT with PET correlation, including quantified response and detailed assessment of peritoneal and nodal resectability.\n- Final histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Request a standardized CT/PET response and resectability report (baseline vs 01‑07‑2025), focusing on peritoneal and nodal operability.\n- Complete IHC and finalize histologic classification, then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to decide timing of interval debulking versus further neoadjuvant therapy and to define postoperative/maintenance systemic strategy.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Maintain plan for urgent comprehensive preoperative and anesthetic assessment; performance status and operative risk remain unknown/needs update.  \n- Proceed with a structured baseline-versus-01‑07‑2025 CT report with PET correlation to quantify response and resectability (requested, unknown/needs update).  \n- Finalize histology with IHC to define subtype, grade, and primary site before definitive staging (currently unknown/needs update).  \n- After histology, complete germline and somatic profiling to inform future systemic and maintenance strategies (currently unknown/needs update).  \n- Reconvene MDT once imaging response/resectability, finalized pathology, and clinical fitness data are available to reassess interval debulking versus further neoadjuvant therapy.", "timestamp": "2026-01-17T23:40:40.318742"}], "assistant": [{"role": "assistant", "user_message": "Summarize expert opinions concisely for MDT.\n{\"chair\":\"- Advanced ovarian malignancy with peritoneal and nodal spread; partial biochemical response to two neoadjuvant platinum–taxane cycles.  \\n- Before surgery decision, urgently need updated performance status, comorbidities, nutritional status, and anesthetic risk assessment.  \\n- Require standardized radiology comparison (baseline vs 2025-07-01 CT and prior PET/CT) to quantify response and resectability.  \\n- Pathology incomplete: need IHC, definitive histologic subtype, grade, and tumor origin confirmation; then order germline and somatic profiling (BRCA/HRD).  \\n- MDT to decide: interval debulking feasibility vs further neoadjuvant therapy once operability, pathology, and genetics are clarified.\",\"oncologist\":\"- Advanced bilateral ovarian carcinoma with peritoneal, nodal, ascitic disease; currently post‑2 cycles neoadjuvant platinum‑taxane, evaluated for interval debulking.  \\n\\n- Tumor markers (CA125, HE4, ROMA) substantially decreased but still elevated, suggesting partial response; detailed radiologic response assessment missing, needs updated CT/MRI.  \\n\\n- Organ function, performance status, neuropathy, marrow and renal reserves are unknown/needs update to judge feasibility of continued platinum‑taxane and perioperative risk.  \\n\\n- Germline and somatic mutation status (BRCA, HRR genes, MSI, others) unknown/needs update to plan postoperative maintenance and future systemic options.  \\n\\n- Surgical team’s assessment of resectability and planned timing/extent of cytoreduction is unknown/needs update to coordinate systemic therapy sequencing.\",\"radiologist\":\"- CT shows multiple small enhancing peritoneal and mesenteric nodules, consistent with disseminated peritoneal disease.[@IMAGING_STUDIES|2025-07-01]\\n\\n- Scattered small retroperitoneal lymph nodes; size and progression versus prior unclear, recommend comparison with earlier imaging.[@IMAGING_STUDIES|2025-07-01]\\n\\n- Prior CT demonstrated large bilateral adnexal masses with extensive peritoneal implants, ascites, and nodal disease, suggesting advanced pelvic malignancy.[@IMAGING_STUDIES|2025-04-26]\\n\\n- PET/CT previously showed widespread FDG-avid pelvic, peritoneal, and nodal disease including supradiaphragmatic nodes, confirming systemic metastatic involvement.[@PET_IF_AVAILABLE|2025-04-29]\\n\\n- Trend of adnexal masses, ascites volume, and nodal size between April and July CTs is unknown; need formal side-by-side comparison.\",\"pathologist\":\"- Current material supports malignant epithelial tumor, favor adenocarcinoma, from pelvic/adnexal mass with malignant ascites cytology [@HISTOLOGY_AND_IHC|2025-04-28;2025-05-07;2025-05-08].  \\n- Tumor grade, exact subtype (e.g., high‑grade serous vs others), and primary site remain undetermined/uncertain [@HISTOLOGY_AND_IHC|2025-04-28].  \\n- No immunohistochemistry yet on core biopsy or ascites cell block; IHC panel urgently needed for definitive classification [@HISTOLOGY_AND_IHC|2025-05-08].  \\n- No molecular testing (HRD/BRCA, MSI, TMB, HER2, PD‑L1) reported; comprehensive predictive panel status unknown/needs update.  \\n- Staging information (imaging, surgical findings, peritoneal/organ involvement extent) missing; pathologic stage cannot be assigned, needs radiology/surgical reports.\",\"nuclear\":\"- FDG-avid bilateral adnexal lesions with extensive peritoneal and pelvic implants indicate metabolically active adnexal primary with peritoneal carcinomatosis [@PET_CT|2025-04-29].  \\n- FDG-avid retroperitoneal, left iliac, costophrenic, internal mammary, and left supraclavicular nodes suggest disseminated nodal metastases, upstaging beyond locoregional disease [@PET_CT|2025-04-29].  \\n- PET/CT extends CT findings by confirming metabolic activity of peritoneal and nodal disease, strengthening suspicion for advanced-stage ovarian malignancy [@PET_CT|2025-04-29; @IMAGING_CONTEXT|2025-04-26].  \\n- PET meaningfully changes staging by demonstrating extra-abdominal nodal involvement (internal mammary, supraclavicular), implying at least distant metastatic spread [@PET_CT|2025-04-29].  \\n- For current visit, need histology, CA-125, prior treatments, and interval imaging to assess for recurrence vs. untreated advanced presentation (unknown/needs update).\"}\n\nOutput:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supradiaphragmatic/supraclavicular nodes (metastatic disease).\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane (CA125/HE4/ROMA decreased but still above normal).\n- Imaging confirms disseminated peritoneal and nodal disease; PET/CT shows metabolically active abdominal and extra‑abdominal nodal involvement.\n- Current pathology: malignant epithelial tumor, likely adenocarcinoma from pelvic/adnexal origin, but subtype, grade, and primary site not yet defined.\n\nControversies:\n- Timing and feasibility of interval debulking surgery versus continuation/intensification of neoadjuvant chemotherapy, given unknown operability and systemic tolerability.\n- Extent and goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Optimal future systemic strategy and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional status, and anesthetic/surgical risk.\n- Formal radiology response assessment (side‑by‑side comparison of baseline vs 2025‑07‑01 CT and PET/CT) including adnexal mass size, ascites volume, peritoneal and nodal burden, and assessment of resectability.\n- Completed histopathology: definitive histologic subtype, grade, primary site; IHC panel results.\n- Germline and somatic testing: BRCA/HRR, HRD status, MSI, TMB, HER2, PD‑L1, and other predictive markers.\n- Current organ function (renal, hepatic, marrow), neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Obtain urgent comprehensive preoperative assessment (PS, comorbidities, nutrition, anesthetic review).\n- Request standardized radiology report with direct comparison of all imaging to quantify treatment response and assess resectability.\n- Complete IHC and finalize histologic subtype/grade/primary site; then order germline and somatic genomic profiling (including BRCA/HRD).\n- Reconvene MDT once operability, pathology, and molecular results are available to decide between interval debulking now vs further neoadjuvant chemotherapy and to outline postoperative/maintenance systemic strategy.", "timestamp": "2026-01-17T23:38:12.471422"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supradiaphragmatic/supraclavicular nodes (metastatic disease).\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane (CA125/HE4/ROMA decreased but still above normal).\n- Imaging confirms disseminated peritoneal and nodal disease; PET/CT shows metabolically active abdominal and extra‑abdominal nodal involvement.\n- Current pathology: malignant epithelial tumor, likely adenocarcinoma from pelvic/adnexal origin, but subtype, grade, and primary site not yet defined.\n\nControversies:\n- Timing and feasibility of interval debulking surgery versus continuation/intensification of neoadjuvant chemotherapy, given unknown operability and systemic tolerability.\n- Extent and goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Optimal future systemic strategy and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional status, and anesthetic/surgical risk.\n- Formal radiology response assessment (side‑by‑side comparison of baseline vs 2025‑07‑01 CT and PET/CT) including adnexal mass size, ascites volume, peritoneal and nodal burden, and assessment of resectability.\n- Completed histopathology: definitive histologic subtype, grade, primary site; IHC panel results.\n- Germline and somatic testing: BRCA/HRR, HRD status, MSI, TMB, HER2, PD‑L1, and other predictive markers.\n- Current organ function (renal, hepatic, marrow), neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Obtain urgent comprehensive preoperative assessment (PS, comorbidities, nutrition, anesthetic review).\n- Request standardized radiology report with direct comparison of all imaging to quantify treatment response and assess resectability.\n- Complete IHC and finalize histologic subtype/grade/primary site; then order germline and somatic genomic profiling (including BRCA/HRD).\n- Reconvene MDT once operability, pathology, and molecular results are available to decide between interval debulking now vs further neoadjuvant chemotherapy and to outline postoperative/maintenance systemic strategy.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.", "timestamp": "2026-01-17T23:38:17.853400"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread (including supraclavicular) nodal metastases.\n- Partial biochemical response after 2 cycles neoadjuvant platinum–taxane; markers improved but remain elevated.\n- PET/CT confirms metabolically active peritoneal and nodal disease (abdominal and extra‑abdominal).\n- Pathology confirms malignant epithelial tumor, likely adnexal adenocarcinoma, but subtype, grade, and primary site are not yet defined.\n\nControversies:\n- Whether to proceed to interval debulking now versus continue/modify neoadjuvant chemotherapy.\n- Appropriate extent and objective of cytoreductive surgery in the setting of extra‑abdominal nodal disease.\n- Future systemic and maintenance strategy pending BRCA/HRD and broader molecular results.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional and anesthetic risk.\n- Formal radiologic response assessment with side‑by‑side comparison of baseline vs 01‑07‑2025 CT and PET/CT, including resectability.\n- Finalized histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy status, and chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Obtain standardized comparative radiology report to quantify response and assess resectability.\n- Complete IHC and finalize histologic classification; then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to determine timing of interval debulking versus further neoadjuvant therapy and to plan postoperative/maintenance systemic strategy.\n[R1T1 DELTA] (missing): A dedicated side‑by‑side review of baseline vs 2025-07-01 CT (and prior PET/CT) to quantify response and resectability is still pending and is critical before any surgical decision. | pathologist->oncologist(missing): Histology still lacks IHC, grade, and defined primary site; urgent immunophenotyping of core and cell‑block material is critical before final staging/strategy decisions. | pathologist->radiologist(missing): Please provide a structured baseline-versus-latest CT/PET comparison focused on peritoneal versus nodal disease resectability to align with pending definitive pathology. | nuclear->radiologist(missing): We lack a structured side‑by‑side comparison of baseline versus 01‑07‑2025 imaging, including PET correlation, specifically addressing operability/resectability of peritoneal and nodal disease; could you provide a standardized response and resectability report?\n[R1T2 DELTA] radiologist->chair(unspecified): From imaging alone, we still have no formal baseline-versus-2025-07-01 response/resectability report integrating CT and PET; this remains critical before interval debulking decisions. | radiologist->nuclear(unspecified): Agree a standardized side‑by‑side CT/PET response and resectability assessment is missing; once requested, I can structure it around peritoneal and nodal operability.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Advanced epithelial ovarian malignancy with bilateral adnexal masses, peritoneal carcinomatosis, ascites, and widespread nodal metastases including supraclavicular nodes.\n- Partial biochemical response after 2 cycles of neoadjuvant platinum–taxane (markers down but still elevated).\n- PET/CT confirms metabolically active peritoneal and nodal disease intra‑ and extra‑abdominally.\n- Pathology confirms malignant epithelial (likely adnexal adenocarcinoma), but subtype, grade, and primary site remain undefined.\n\nControversies:\n- Interval debulking now versus further/modified neoadjuvant chemotherapy.\n- Extent/goal of cytoreductive surgery in the context of extra‑abdominal nodal disease.\n- Future systemic and maintenance approach pending BRCA/HRD and broader molecular profile.\n\nMissing Info:\n- Updated performance status, comorbidities, nutritional state, and anesthetic risk.\n- Formal, structured side‑by‑side comparison of baseline vs 01‑07‑2025 CT with PET correlation, including quantified response and detailed assessment of peritoneal and nodal resectability.\n- Final histology with IHC (subtype, grade, primary site).\n- Germline and somatic profiling (BRCA/HRR, HRD, MSI, TMB, HER2, PD‑L1, etc.).\n- Current organ function, neuropathy, and overall chemotherapy tolerance.\n\nWorking Plan:\n- Perform urgent comprehensive preoperative and anesthetic assessment.\n- Request a standardized CT/PET response and resectability report (baseline vs 01‑07‑2025), focusing on peritoneal and nodal operability.\n- Complete IHC and finalize histologic classification, then proceed with germline and somatic genomic profiling.\n- Reconvene MDT once operability, pathology, and molecular data are available to decide timing of interval debulking versus further neoadjuvant therapy and to define postoperative/maintenance systemic strategy.", "timestamp": "2026-01-17T23:39:34.765367"}]}, "trace_events": [{"ts": "2026-01-17T23:37:13.162219", "event": "pipeline_start", "payload": {"visit_time": "2025-07-01 15:38:50.183000", "meta_info": "63212719700818194X"}}, {"ts": "2026-01-17T23:37:13.162622", "event": "case_fingerprint", "payload": {"case_fingerprint": "5394a9a70135"}}, {"ts": "2026-01-17T23:37:13.405760", "event": "reports_loaded", "payload": {"lab_n": 0, "img_n": 0, "path_n": 0, "mut_n": 1, "cutoff_dt": "2025-07-02 15:38:50"}}, {"ts": "2026-01-17T23:37:13.460489", "event": "reports_selected", "payload": {"lab": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "imaging": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "pathology": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "mutation": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}}}, {"ts": "2026-01-17T23:37:41.148370", "event": "rag_query", "payload": {"query": "Presumed high-grade Müllerian adenocarcinoma, platinum-NA, with bilateral adnexal masses, diffuse peritoneal and nodal metastases; no BRCA/HRD/MSI/PD-L1 data; good response in CA125/HE4; no reported organ dysfunction or performance constraints—guidance on systemic therapy and surgery?"}}, {"ts": "2026-01-17T23:37:41.148376", "event": "rag_hits", "payload": {"topk": 5, "n": 5}}, {"ts": "2026-01-17T23:37:52.471259", "event": "mdt_discussion_start", "payload": {"num_rounds": 2, "num_turns": 2}}, {"ts": "2026-01-17T23:40:40.318828", "event": "mdt_discussion_end", "payload": {"merged_chars": 1846}}, {"ts": "2026-01-17T23:40:40.319615", "event": "final_output_start", "payload": {}}, {"ts": "2026-01-17T23:40:44.854955", "event": "final_output_end", "payload": {"final_output_chars": 1322}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Global Guideline RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
